SORAMIC is a randomized controlled trial including diagnostic, local ablation and palliative cohorts. In the palliative cohort, patients not eligible for transarterial chemoembolization (TACE) were randomized 11:10 to selective internal radiation therapy with yttrium-90 resin microspheres (SIRT) plus sorafenib (SIRT+sorafenib, n=216) or sorafenib alone (n=208). Median OS in the intent-to-treat population was 12.1 months in the SIRT+sorafenib arm, and 11.4 months in the sorafenib arm (hazard ratio [HR] 1.01; 95%CI 0.81-1.25; p=0.9529). Subgroup analyses of the per-protocol population indicated a survival benefit of SIRT+sorafenib for patients without cirrhosis, cirrhosis of non-alcoholic etiology, patients ≤65 years old. Grade 3-4 adverse events were reported in 103/159 (64.8%) patients who received SIRT+sorafenib, 106/197 (53.8%) patients who received sorafenib alone (p=0.04), and 8/24 (33.3%) patients who received only SIRT.
(Ricke J et al. – J Hepatol, 7 December 2019)

Read more